AI Engines For more Details: Perplexity Kagi Labs You
Hormone Replacement Therapy (HRT): Testosterone propionate is used as a component of hormone replacement therapy in males with hypogonadism, a condition characterized by low testosterone levels. It helps restore testosterone levels to within the normal range, improving symptoms such as reduced libido, erectile dysfunction, fatigue, and mood changes.
Androgen Deficiency: Testosterone propionate is also used to treat androgen deficiency syndromes in men, including delayed puberty and certain genetic disorders associated with inadequate testosterone production.
Anabolic Effects: Testosterone propionate has anabolic properties, meaning it promotes the growth and development of muscle tissue and bone mass. It is sometimes used by athletes and bodybuilders to enhance muscle strength, endurance, and athletic performance. However, the non-medical use of testosterone for performance enhancement is prohibited in many sports and can lead to serious health risks and legal consequences.
Dosage Forms: Testosterone propionate is available in various dosage forms, including injections, oral capsules (e.g., Andriol), transdermal patches (e.g., Androderm), gels (e.g., Androgel), and buccal tablets (e.g., Striant). The choice of dosage form depends on factors such as patient preference, convenience, and individual medical needs.
Adverse Effects: Like all medications, testosterone propionate may cause side effects, especially with long-term use or high doses. Common side effects include acne, oily skin, hair loss (in genetically predisposed individuals), fluid retention, increased blood pressure, changes in libido, mood swings, and aggression. In women, masculinization (virilization) may occur with prolonged exposure to high doses of testosterone.
Cardiovascular Risks: Long-term use of testosterone, particularly in high doses, may increase the risk of cardiovascular complications such as heart attack, stroke, and blood clots. Patients with pre-existing cardiovascular conditions should use testosterone therapy cautiously and under the supervision of a healthcare provider.
Hepatic Effects: Testosterone propionate can affect liver function, especially when taken orally (e.g., Andriol). Patients with liver disease or dysfunction should avoid oral testosterone formulations or use them with caution.
Hormonal Imbalance: Testosterone propionate therapy can disrupt the body's natural hormone balance, leading to potential complications such as infertility, testicular atrophy (shrinkage of the testes), gynecomastia (enlargement of breast tissue in men), and suppression of natural testosterone production (hypogonadism) after discontinuation of therapy.
Monitoring: Patients receiving testosterone propionate therapy should undergo regular medical monitoring, including blood tests to assess hormone levels, liver function tests, lipid profiles, and cardiovascular risk factors.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Anaerobutyricum hallii | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Blautia wexlerae | Reduces |
| species | Christensenella minuta | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Lactococcus cremoris | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | Coprococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Enterocloster | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 1 | 0 | Coprococcus comes | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Streptococcus salivarius | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 0 | 1 | Segatella bryantii | species | Decreases |
| 0 | 1 | Bacillus paralicheniformis | species | Decreases |
| 1 | 0 | Enterocloster bolteae | species | Decreases |
| 0 | 1 | Leyella stercorea | species | Decreases |
| 0 | 1 | Anaerobutyricum hallii | species | Decreases |
| 0 | 1 | Coprococcus catus | species | Decreases |
| 0 | 1 | Fannyhessea vaginae | species | Decreases |
| 0 | 1 | Dorea longicatena | species | Decreases |
| 0 | 1 | Blautia sp. SC05B48 | species | Decreases |
| 0 | 1 | Streptococcus sp. FDAARGOS_192 | species | Decreases |
| 0 | 1 | Roseburia rectibacter | species | Decreases |
| 0 | 1 | Eubacterium ventriosum | species | Decreases |
| 0 | 1 | Anaerostipes hadrus | species | Decreases |
| 0 | 1 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Adlercreutzia equolifaciens | species | Decreases |
| 0 | 1 | Komagataeibacter oboediens | species | Decreases |
| 0 | 1 | Blautia obeum | species | Decreases |
| 0 | 1 | Ligilactobacillus ruminis | species | Decreases |
| 0 | 1 | Butyrivibrio crossotus | species | Decreases |
| 0 | 1 | Eubacterium sp. MSJ-33 | species | Decreases |
| 0 | 1 | Pseudobutyrivibrio xylanivorans | species | Decreases |
| 0 | 1 | Wansuia hejianensis | species | Decreases |
| 0 | 1 | Lachnoanaerobaculum gingivalis | species | Decreases |
| 0 | 1 | Blautia liquoris | species | Decreases |
| 0 | 1 | Faecalibaculum rodentium | species | Decreases |
| 0 | 1 | Parvimonas micra | species | Decreases |
| 0 | 1 | Eubacterium limosum | species | Decreases |
| 0 | 1 | Intestinibaculum porci | species | Decreases |
| 0 | 1 | Ruminococcus albus | species | Decreases |
| 0 | 1 | Faecalibacillus intestinalis | species | Decreases |
| 0 | 1 | [Ruminococcus] lactaris | species | Decreases |
| 0 | 1 | Mogibacterium diversum | species | Decreases |
| 0 | 1 | Subdoligranulum variabile | species | Decreases |
| 0 | 1 | Eubacterium maltosivorans | species | Decreases |
| 0 | 1 | Butyrivibrio fibrisolvens | species | Decreases |
| 0 | 1 | Christensenella minuta | species | Decreases |
| 0 | 1 | Faecalitalea cylindroides | species | Decreases |
| 0 | 1 | Blautia wexlerae | species | Decreases |
| 0 | 1 | Treponema denticola | species | Decreases |
| 0 | 1 | Qiania dongpingensis | species | Decreases |
| 0 | 1 | Coprococcus eutactus | species | Decreases |
| 0 | 1 | Eubacterium sp. c-25 | species | Decreases |
| 0 | 1 | Wujia chipingensis | species | Decreases |
| 0 | 1 | Eubacterium callanderi | species | Decreases |
| 0 | 1 | Clostridium sp. SY8519 | species | Decreases |
| 0 | 1 | Novisyntrophococcus fermenticellae | species | Decreases |
| 0 | 1 | Olsenella sp. oral taxon 807 | species | Decreases |
| 0 | 1 | Prevotella intermedia | species | Decreases |
| 0 | 1 | Actinomyces oris | species | Decreases |
| 0 | 1 | Ruminococcus gauvreauii | species | Decreases |
| 0 | 1 | Clostridium sp. M62/1 | species | Decreases |
| 0 | 1 | [Eubacterium] hominis | species | Decreases |
| 0 | 1 | Phascolarctobacterium succinatutens | species | Decreases |
| 0 | 1 | Bacteroides humanifaecis | species | Decreases |
| 0 | 1 | Enterococcus cecorum | species | Decreases |
| 0 | 1 | Ruthenibacterium lactatiformans | species | Decreases |
| 0 | 1 | Faecalibacterium duncaniae | species | Decreases |
| 0 | 1 | Phoenicibacter congonensis | species | Decreases |
| 0 | 1 | Leyella lascolaii | species | Decreases |
| 0 | 1 | Coprococcus sp. ART55/1 | species | Decreases |
| 0 | 1 | Longicatena caecimuris | species | Decreases |
| 0 | 1 | Maliibacterium massiliense | species | Decreases |
| 0 | 1 | Actinomyces naeslundii | species | Decreases |
| 0 | 1 | Emergencia timonensis | species | Decreases |
| 0 | 1 | Lactococcus cremoris | species | Decreases |
| 0 | 1 | Massilistercora timonensis | species | Decreases |
| 0 | 1 | Corynebacterium durum | species | Decreases |
| 0 | 1 | Romboutsia ilealis | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-1-18 | species | Decreases |
| 0 | 1 | Mageeibacillus indolicus | species | Decreases |
| 0 | 1 | Roseburia hominis | species | Decreases |
| 0 | 1 | Ruminococcus bicirculans (ex Wegman et al. 2014) | species | Decreases |
| 0 | 1 | Butyricicoccus sp. GAM44 | species | Decreases |
| 0 | 1 | Streptococcus suis | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I3-3-33 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-1-79 | species | Decreases |
| 0 | 1 | Marvinbryantia formatexigens | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I4-3-84 | species | Decreases |
| 0 | 1 | Ruminococcus bovis | species | Decreases |
| 0 | 1 | Clostridium cadaveris | species | Decreases |
| 0 | 1 | Faecalibacterium sp. IP-3-29 | species | Decreases |
| 0 | 1 | Faecalibacterium sp. I2-3-92 | species | Decreases |
| 0 | 1 | Alistipes ihumii | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.3 | 0.6 | 1.17 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.2 | 1 |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.2 | 0.5 |
| Allergies | 1.2 | 1.7 | -0.42 |
| Allergy to milk products | 0.9 | 0.4 | 1.25 |
| Alopecia (Hair Loss) | 0.3 | 0.1 | 2 |
| Alzheimer's disease | 1.3 | 2.9 | -1.23 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.6 | -0.5 |
| Ankylosing spondylitis | 1.1 | 0.6 | 0.83 |
| Anorexia Nervosa | 0.8 | 1.1 | -0.38 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 0.8 | 0.4 | 1 |
| Atherosclerosis | 1 | 0.6 | 0.67 |
| Atrial fibrillation | 1.3 | 1 | 0.3 |
| Autism | 3.4 | 3.1 | 0.1 |
| Autoimmune Disease | 0.1 | 0.2 | -1 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| benign prostatic hyperplasia | 0.1 | -0.1 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 0.7 | 1 | -0.43 |
| Brain Trauma | 0.2 | 0.8 | -3 |
| Cancer (General) | 0.6 | -0.6 | |
| Carcinoma | 0.8 | 0.7 | 0.14 |
| Celiac Disease | 1 | 0.8 | 0.25 |
| Cerebral Palsy | 0.2 | 0.8 | -3 |
| Chronic Fatigue Syndrome | 2.2 | 3.3 | -0.5 |
| Chronic Kidney Disease | 1 | 1.6 | -0.6 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 0.6 | 0.33 |
| Chronic Urticaria (Hives) | 0.1 | 0.6 | -5 |
| Coagulation / Micro clot triggering bacteria | 0.3 | 0.8 | -1.67 |
| Cognitive Function | 0.8 | 0.3 | 1.67 |
| Colorectal Cancer | 2.8 | 0.8 | 2.5 |
| Constipation | 1 | 0.2 | 4 |
| Coronary artery disease | 0.9 | 1.1 | -0.22 |
| COVID-19 | 2.1 | 5.4 | -1.57 |
| Crohn's Disease | 2.5 | 1.8 | 0.39 |
| Cushing's Syndrome (hypercortisolism) | 0.5 | -0.5 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.3 | 0.9 | -2 |
| Denture Wearers Oral Shifts | 0.5 | 0.5 | |
| Depression | 3.5 | 3.6 | -0.03 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 0.1 | 0.5 | -4 |
| Endometriosis | 0.6 | 1.1 | -0.83 |
| Eosinophilic Esophagitis | 0.1 | -0.1 | |
| Epilepsy | 0.3 | 0.2 | 0.5 |
| erectile dysfunction | 0.1 | 0.1 | |
| Fibromyalgia | 0.5 | 1.5 | -2 |
| Functional constipation / chronic idiopathic constipation | 2 | 2.6 | -0.3 |
| gallstone disease (gsd) | 0.7 | 0.2 | 2.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.7 | -0.4 |
| Generalized anxiety disorder | 0.5 | 0.5 | 0 |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.7 | 0.3 | 1.33 |
| Graves' disease | 0.7 | 1 | -0.43 |
| Gulf War Syndrome | 0.4 | 0 | 0 |
| Halitosis | 0.2 | 0.1 | 1 |
| Hashimoto's thyroiditis | 1.6 | 0.7 | 1.29 |
| Heart Failure | 1.2 | 1.1 | 0.09 |
| hemorrhagic stroke | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.2 | 0.2 | |
| High Histamine/low DAO | 0.2 | 0.5 | -1.5 |
| hyperglycemia | 0.3 | 0.2 | 0.5 |
| hypertension (High Blood Pressure | 1.5 | 1.4 | 0.07 |
| Hypothyroidism | 0.1 | 0.3 | -2 |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 0.8 | 1.3 | -0.63 |
| Inflammatory Bowel Disease | 1.3 | 4.2 | -2.23 |
| Insomnia | 1 | 1 | 0 |
| Intelligence | 0.6 | 0.5 | 0.2 |
| Intracranial aneurysms | 0.8 | 0.3 | 1.67 |
| Irritable Bowel Syndrome | 1.5 | 2 | -0.33 |
| ischemic stroke | 0.8 | 0.4 | 1 |
| Liver Cirrhosis | 1.9 | 1.2 | 0.58 |
| Long COVID | 2.1 | 2.5 | -0.19 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.7 | -0.7 | |
| Mast Cell Issues / mastitis | 0.1 | 0.8 | -7 |
| ME/CFS with IBS | 0.3 | 1.5 | -4 |
| ME/CFS without IBS | 0.2 | 0.7 | -2.5 |
| membranous nephropathy | 0.1 | 0.1 | |
| Menopause | 0.2 | 0.3 | -0.5 |
| Metabolic Syndrome | 1.5 | 2.3 | -0.53 |
| Mood Disorders | 3.1 | 2.9 | 0.07 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.4 | |
| Multiple Sclerosis | 1.6 | 3 | -0.88 |
| Multiple system atrophy (MSA) | 0.1 | 0.5 | -4 |
| myasthenia gravis | 0.1 | 0.2 | -1 |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.1 | 0.4 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.1 | 0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.6 | 1.6 | 0 |
| NonCeliac Gluten Sensitivity | 0.1 | 0.1 | 0 |
| Obesity | 3 | 2.9 | 0.03 |
| obsessive-compulsive disorder | 2.1 | 1.7 | 0.24 |
| Osteoarthritis | 0.7 | 0.8 | -0.14 |
| Osteoporosis | 0.8 | 0.2 | 3 |
| pancreatic cancer | 0.1 | 0.1 | 0 |
| Parkinson's Disease | 3.1 | 3.1 | 0 |
| Polycystic ovary syndrome | 2.9 | 1.5 | 0.93 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.2 | -0.2 | |
| primary biliary cholangitis | 0.1 | 0.3 | -2 |
| Primary sclerosing cholangitis | 0.3 | 1.7 | -4.67 |
| Psoriasis | 0.8 | 1.8 | -1.25 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 0.9 | 2.11 |
| Rosacea | 1.1 | 0.2 | 4.5 |
| Schizophrenia | 1.6 | 1.3 | 0.23 |
| scoliosis | 0.5 | 0.6 | -0.2 |
| sensorineural hearing loss | 0.3 | 0.3 | |
| Sjögren syndrome | 0.8 | 0.6 | 0.33 |
| Sleep Apnea | 0.8 | 0.6 | 0.33 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.4 | 0.7 | -0.75 |
| Systemic Lupus Erythematosus | 0.7 | 0.8 | -0.14 |
| Tic Disorder | 1 | 0.8 | 0.25 |
| Tourette syndrome | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 1.6 | 1.5 | 0.07 |
| Type 2 Diabetes | 2.6 | 2.5 | 0.04 |
| Ulcerative colitis | 1.4 | 2.9 | -1.07 |
| Unhealthy Ageing | 1.7 | 0.9 | 0.89 |
| Vitiligo | 0.9 | 0.8 | 0.13 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
